Haemonetics outlines FY 2027 organic growth of 6%-9% while scaling CSL Persona PLUS rollout through calendar 2027 (NYSE:HAE)
· seekingalpha.com
Haemonetics Q2 FY2027 earnings: raised revenue growth outlook, CSL rollout progress, and margin headwinds.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...